EA026683B1 - МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА - Google Patents
МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА Download PDFInfo
- Publication number
- EA026683B1 EA026683B1 EA201491859A EA201491859A EA026683B1 EA 026683 B1 EA026683 B1 EA 026683B1 EA 201491859 A EA201491859 A EA 201491859A EA 201491859 A EA201491859 A EA 201491859A EA 026683 B1 EA026683 B1 EA 026683B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- treating
- treatment
- lipid
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623203P | 2012-04-12 | 2012-04-12 | |
| US201261623414P | 2012-04-12 | 2012-04-12 | |
| PCT/US2013/031861 WO2013154752A1 (en) | 2012-04-12 | 2013-03-15 | A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491859A1 EA201491859A1 (ru) | 2015-02-27 |
| EA026683B1 true EA026683B1 (ru) | 2017-05-31 |
Family
ID=49328028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491859A EA026683B1 (ru) | 2012-04-12 | 2013-03-15 | МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20150072962A1 (https=) |
| EP (2) | EP3239163A1 (https=) |
| JP (4) | JP6125610B2 (https=) |
| KR (1) | KR102180485B1 (https=) |
| CN (2) | CN106083976B (https=) |
| AU (2) | AU2013246435B2 (https=) |
| BR (1) | BR112014025081B1 (https=) |
| CA (1) | CA2867694C (https=) |
| DK (1) | DK2836502T3 (https=) |
| EA (1) | EA026683B1 (https=) |
| ES (1) | ES2641841T3 (https=) |
| HU (1) | HUE035073T2 (https=) |
| IL (1) | IL234892B (https=) |
| IN (1) | IN2014KN02366A (https=) |
| MX (1) | MX357046B (https=) |
| PL (1) | PL2836502T3 (https=) |
| PT (1) | PT2836502T (https=) |
| SI (1) | SI2836502T1 (https=) |
| WO (1) | WO2013154752A1 (https=) |
| ZA (1) | ZA201406981B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| EA026683B1 (ru) * | 2012-04-12 | 2017-05-31 | Вирджиния Коммонвелт Юниверсити | МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА |
| PL3639828T3 (pl) * | 2013-12-24 | 2022-05-02 | Virginia Commonwealth University | Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby |
| TWI547280B (zh) * | 2014-04-24 | 2016-09-01 | 長弘生物科技股份有限公司 | 穩定醫藥組合物 |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| CN107106576A (zh) * | 2014-10-10 | 2017-08-29 | 弗吉尼亚联邦大学 | 用于因减弱的瘦蛋白活性和脂质贮积障碍中的至少一种导致的障碍的疗法的氧化胆固醇硫酸酯类 |
| JP6784963B2 (ja) * | 2014-12-24 | 2020-11-18 | 国立大学法人京都大学 | ビタミンｄ３誘導体及びその薬学的用途 |
| US20200222430A1 (en) * | 2016-08-02 | 2020-07-16 | Durect Corporation | Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride |
| EP3494125B1 (en) | 2016-08-02 | 2022-06-22 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| CA3031211A1 (en) * | 2016-08-02 | 2018-02-08 | Virginia Commonwealth University | Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions |
| US11458146B2 (en) | 2017-01-13 | 2022-10-04 | Duke University | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders |
| KR101892577B1 (ko) | 2017-04-21 | 2018-08-28 | 부산대학교 산학협력단 | 레블라스타틴 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 조성물 |
| CN107286160A (zh) * | 2017-06-05 | 2017-10-24 | 毛佳婧 | 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法 |
| RU2020110253A (ru) * | 2017-08-31 | 2021-09-30 | Ариэль Сайентифик Инновейшнз Лтд | Экстракт s. spinosum для лечения жировой болезни печени |
| BR112022005039A2 (pt) * | 2019-09-30 | 2022-06-21 | Durect Corp | Tratamento de hepatite alcoólica |
| EP4171573A4 (en) * | 2020-06-26 | 2025-04-09 | Durect Corporation | USE OF OXYGENATED CHOLESTEROL SULFATES FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES AND ADDICTION |
| CN112294827B (zh) * | 2020-11-12 | 2021-12-24 | 四川大学华西医院 | 5-胆甾烯 -3β-醇硫酸酯盐的用途 |
| KR102732697B1 (ko) | 2021-10-29 | 2024-11-25 | 부산대학교 산학협력단 | 크산틴 유도체를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학적 조성물 |
| WO2024008614A1 (en) * | 2022-07-08 | 2024-01-11 | Société des Produits Nestlé S.A. | Use of 25-hydroxycholesterol for diabetic treatment and/or prevention |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070275939A1 (en) * | 2004-10-25 | 2007-11-29 | Shunlin Ren | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL146223A0 (en) * | 1999-04-30 | 2002-07-25 | Arch Dev Corp | Steroid derivatives |
| CA2637884A1 (en) | 2006-02-13 | 2007-08-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US8003795B2 (en) | 2007-06-22 | 2011-08-23 | Cvi Pharmaceuticals Limited | Compounds and compositions for reducing lipid levels |
| WO2011077245A2 (en) * | 2009-12-23 | 2011-06-30 | Fondazione Centro San Raffaele Del Monte Tabor | Compositions |
| EA026683B1 (ru) * | 2012-04-12 | 2017-05-31 | Вирджиния Коммонвелт Юниверсити | МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА |
-
2013
- 2013-03-15 EA EA201491859A patent/EA026683B1/ru unknown
- 2013-03-15 MX MX2014012324A patent/MX357046B/es active IP Right Grant
- 2013-03-15 CN CN201610412359.9A patent/CN106083976B/zh not_active Expired - Fee Related
- 2013-03-15 PL PL13775974T patent/PL2836502T3/pl unknown
- 2013-03-15 SI SI201330794T patent/SI2836502T1/sl unknown
- 2013-03-15 PT PT137759742T patent/PT2836502T/pt unknown
- 2013-03-15 BR BR112014025081-2A patent/BR112014025081B1/pt not_active IP Right Cessation
- 2013-03-15 HU HUE13775974A patent/HUE035073T2/en unknown
- 2013-03-15 KR KR1020147031567A patent/KR102180485B1/ko not_active Expired - Fee Related
- 2013-03-15 EP EP17167122.5A patent/EP3239163A1/en not_active Withdrawn
- 2013-03-15 DK DK13775974.2T patent/DK2836502T3/en active
- 2013-03-15 JP JP2015505762A patent/JP6125610B2/ja not_active Expired - Fee Related
- 2013-03-15 CA CA2867694A patent/CA2867694C/en active Active
- 2013-03-15 AU AU2013246435A patent/AU2013246435B2/en not_active Ceased
- 2013-03-15 US US14/391,929 patent/US20150072962A1/en not_active Abandoned
- 2013-03-15 CN CN201380019476.3A patent/CN104220450B/zh not_active Expired - Fee Related
- 2013-03-15 WO PCT/US2013/031861 patent/WO2013154752A1/en not_active Ceased
- 2013-03-15 ES ES13775974.2T patent/ES2641841T3/es active Active
- 2013-03-15 EP EP13775974.2A patent/EP2836502B1/en active Active
-
2014
- 2014-09-25 ZA ZA2014/06981A patent/ZA201406981B/en unknown
- 2014-09-28 IL IL234892A patent/IL234892B/en active IP Right Grant
- 2014-10-27 IN IN2366KON2014 patent/IN2014KN02366A/en unknown
-
2016
- 2016-08-19 US US15/241,171 patent/US20160355544A1/en not_active Abandoned
-
2017
- 2017-04-05 JP JP2017074866A patent/JP2017160213A/ja active Pending
- 2017-10-10 US US15/728,827 patent/US20180127457A1/en not_active Abandoned
- 2017-11-30 AU AU2017268646A patent/AU2017268646B2/en not_active Ceased
-
2018
- 2018-09-25 US US16/140,964 patent/US20190135856A1/en not_active Abandoned
-
2019
- 2019-01-10 JP JP2019002297A patent/JP2019089777A/ja not_active Withdrawn
- 2019-10-10 US US16/599,044 patent/US20200157140A1/en not_active Abandoned
-
2020
- 2020-12-15 US US17/122,647 patent/US20210238219A1/en not_active Abandoned
-
2021
- 2021-05-14 JP JP2021082520A patent/JP2021138713A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070275939A1 (en) * | 2004-10-25 | 2007-11-29 | Shunlin Ren | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
Non-Patent Citations (4)
| Title |
|---|
| MA Y. et al., "25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway", Am. J. Physiol. Endocrinol. Metab., 14 October 2008, vol. 295, No. 6, pp. E1369-E1379. See abstract * |
| REN S. et al., "Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes", Biochem. Biophys. Res. Commun., 6 July 2007, vol. 360, No. 4, pp. 802-808. See abstract * |
| XU L. et al., "25-Hydroxycholesterol-3-sulfate attenuates inflammatory response via PPARγ signaling in human THP-1 macrophages", Am. J. Physiol. Endocrinol. Metab., 24 January 2012, vol. 302, No. 7, pp. E788-E799. See abstract * |
| XU L. et al., "Regulation of hepatocyte lipid metabolism and inflammatory response by 25-hydroxycholesterol and 25-hydroxycholesterol-3-sulfate", Lipids., 11 August 2010, vol. 45, No. 9, pp. 821-832. See abstract * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA026683B1 (ru) | МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА | |
| CN110437297B (zh) | 法尼醇x受体的抑制剂和在医学中的用途 | |
| Yuk et al. | Effects of lactose-β-sitosterol and β-sitosterol on ovalbumin-induced lung inflammation in actively sensitized mice | |
| Nguyen et al. | Anti-inflammatory terpenylated coumarins from the leaves of Zanthoxylum schinifolium with α-glucosidase inhibitory activity | |
| WO2014195950A1 (en) | Bile acid-basic amino acid conjugates and uses thereof | |
| Lu et al. | Crosstalk of hepatocyte nuclear factor 4a and glucocorticoid receptor in the regulation of lipid metabolism in mice fed a high-fat-high-sugar diet | |
| EP2460812B1 (en) | Sterol derivatives and their synthesis and use | |
| CN112603922B (zh) | 木脂素苷类化合物在制备降脂药物中的用途 | |
| HK1202294B (en) | A novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis | |
| JP6430736B2 (ja) | 新規ステロール系化合物およびこれを含有するコレステロール吸収阻害剤 | |
| US20210369740A1 (en) | Synthesis of Anti-inflammatory and Anti-cancer Agents through Fungal Transformation of Mibolerone | |
| EP3353186B1 (en) | Highly efficient nrf2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation | |
| CN121337819A (zh) | 熊去氧胆酸UDCA在抑制Skp2蛋白及抗非小细胞肺癌中的应用 |